In agreement with this assumption are previous studies reporting that MSX-122 is not preventing CXCL12 binding, and our data presented here that MSX-122 is not affecting CXCR4-tropic HIV-1 infection, in contrast to most other tested CXCR4 antagonists. This evidence concerns the gene CXCR4 and HIV-1 infection.